Mobile

A phase IV, open, multicentre, multicountry study to evaluate the immune response to a challenge dose of GSK Biologicals’ Twinrix™ vaccine versus monovalent hepatitis A and B vaccines from different m...

Mise à jour : Il y a 5 ans
Référence : EUCTR2008-000526-39

A phase IV, open, multicentre, multicountry study to evaluate the immune response to a challenge dose of GSK Biologicals’ Twinrix™ vaccine versus monovalent hepatitis A and B vaccines from different manufacturers in healthy and non-healthy adults aged > 41 years, approximately 48 months after primary vaccination in study 100382 (HAB-160)

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To evaluate the anti-HAV and anti-HBs immune memory (in terms of anti-HAV and anti-HBs immune response elicited by the challenge dose) in a population > 41 years of age (healthy and non-healthy), approximately 48 months after the first dose of the primary vaccination course.

Critère d'inclusion

  • Healthy and non-healthy (including those taking medications) adults older than 41 years who participated in the primary vaccination study HAB-160 approximately 48 months ago

Liens